Compare GDYN & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDYN | CMPS |
|---|---|---|
| Founded | 2006 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 727.6M | 662.5M |
| IPO Year | N/A | 2020 |
| Metric | GDYN | CMPS |
|---|---|---|
| Price | $9.29 | $7.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $11.25 | ★ $16.43 |
| AVG Volume (30 Days) | 954.0K | ★ 1.3M |
| Earning Date | 02-19-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 457.52 | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $405,955,000.00 | N/A |
| Revenue This Year | $19.77 | N/A |
| Revenue Next Year | $10.24 | N/A |
| P/E Ratio | $56.20 | ★ N/A |
| Revenue Growth | ★ 23.63 | N/A |
| 52 Week Low | $7.37 | $2.25 |
| 52 Week High | $25.50 | $8.20 |
| Indicator | GDYN | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 47.50 | 56.72 |
| Support Level | $9.22 | $6.82 |
| Resistance Level | $9.55 | $7.75 |
| Average True Range (ATR) | 0.37 | 0.49 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 33.90 | 51.81 |
Grid Dynamics Holdings Inc is a provider of technology consulting, platform and product engineering, and advanced analytics services. The company delivers tailored solutions in several industry verticals like Tech, Media and Telecom, Retail, Finance and Consumer Packaged goods (CPG)/manufacturing. The company derives maximum revenue from Retails. Geographically company earns revenue from North America, Europe and other regions.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.